SCLXW
Scilex Holding Company
NASDAQ · Healthcare · Drug Manufacturers - General · US
$0.11
−5.47%Year over year
Reported trailing growth
- Revenue
- -28.5%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +303.7%
- EBITDA
- +108.0%
- EPS
- +100.1%
Three-year CAGR
- Revenue
- -7.3%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -87.8%
- Free cash flow
- -80.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026